Other Clinical Trial - Peripheral Blood Mononuclear Cell Collection

Clinical Trial Description

Collect blood samples (whole blood and PBMC) from healthy donors for the development and production of UCAR-T cells ;

Study Design

Related Conditions & MeSH terms

Peripheral Blood Mononuclear Cell

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02272530` - Analysis of Proteome and Pathophysiological Characteristics of Human Blood Cells
	Recruiting	`NCT04963959` - PBMC Collection for Production of UCAR T Cells	N/A

See also

Status

Clinical Trial

Phase

Completed

NCT02272530 - Analysis of Proteome and Pathophysiological Characteristics of Human Blood Cells

Recruiting

NCT04963959 - PBMC Collection for Production of UCAR T Cells

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT04448509
Study type	Interventional
Source	Zhejiang University
Contact	He Huang, PhD
Phone	86-13605714822
Email	huanghe@zju.edu.cn
Status	Recruiting
Phase	N/A
Start date	June 18, 2020
Completion date	August 31, 2022

Peripheral Blood Mononuclear Cell Collection Protocol for UCART Cell Tumor Immunotherapy Study

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms